Osaka biotech AOI raises $3.2M to expand fertility antibody test
What's the deal? AOI BiosciencesDealroom has a profile for this one. Try Dealroom →, an Osaka-based diagnostics and drug discovery startup, has raised roughly ¥500 million (about $3.2 million) in an early-stage round. The financing combined a third-party share allotment with a secondary transaction, and lifted the company's cumulative funding to about ¥1 billion.
Who's backing it? Existing investors Nippon Venture CapitalDealroom has a profile for this one. Try Dealroom →, SBI Shinsei Corporate InvestmentDealroom has a profile for this one. Try Dealroom →, and i-nest capitalDealroom has a profile for this one. Try Dealroom → returned. New backers include GoAhead VenturesDealroom has a profile for this one. Try Dealroom →, Seiho Investment WorksDealroom has a profile for this one. Try Dealroom →, Sumisei Innovation FundDealroom has a profile for this one. Try Dealroom →, SBI Okasan Alternative Investment, BIG ImpactDealroom has a profile for this one. Try Dealroom →, and CTBC Venture Capital.
What does it do? AOI focuses on autoimmune disease and infection, built around what it calls "neo-self antibody" testing. Its β2GPI test screens for antibodies linked to miscarriage and infertility, and is now used at more than 300 Japanese medical institutions.
What's the endgame? The company will use the money to accelerate the test's domestic uptake and expansion across Asia, where it already operates in Malaysia, South Korea, Taiwan, and Indonesia. It is also funding an allosteric drug discovery platform developed with ToshibaDealroom has a profile for this one. Try Dealroom →, which uses quantum-inspired optimisation to target proteins long considered "undruggable."
Why it matters: The test is approved in Japan as an advanced medical treatment for recurrent pregnancy loss, making it eligible for local subsidies that reduce patient costs. In clinical research, patients who received treatment after a positive result saw pregnancy rates more than double in infertility cases and live-birth rates rise more than 1.7 times in recurrent miscarriage cases.
Nippon Venture Capital's Liu Yuyang, backing AOI for the third time, said the firm wants to help it become a globally active obstetrics and gynaecology biotech, "not only aiming to achieve an exit including a listing" (translated from Japanese).
The signal: The round sits in the lower tier for size — around the 24th percentile among comparable deals — reflecting a modest early raise rather than a growth-stage bet. Yet with a subsidised, revenue-generating diagnostic already scaling across Asia and a quantum-assisted drug pipeline in reserve, AOI is positioning itself as a test case for how Japanese university-spinout biotechs commercialise and expand abroad.
Image credit: aoibio.com
